Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors

Background: The homologous recombination deficiency (HRD) score serves as a promising biomarker to identify patients who are eligible for treatment with PARP inhibitors (PARPi). Previous studies have suggested a 3-biomarker Genomic Instability Score (GIS) threshold of ≥ 42 as a valid biomarker to pr...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Diwei Zhao, Anqi Wang, Yuanwei Li, Xinyang Cai, Junliang Zhao, Tianyou Zhang, Yi Zhao, Yu Dong, Fangjian Zhou, Yonghong Li, Jun Wang
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2024-09-01
سلاسل:	Journal of the National Cancer Center
الموضوعات:	Homologous recombination deficiency score Threshold PARP inhibitors Homologous recombination repair pathway mutation BRCA
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2667005424000437
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!